Cytokinetics Inc (NAS:CYTK)
$ 48.3695 -0.6105 (-1.25%) Market Cap: 5.07 Bil Enterprise Value: 5.27 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 05:00PM GMT
Release Date Price: $42.3 (-1.97%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley and Adhiraj Chauhan from the team.

Our next presenting company is Cytokinetics. And speaking on behalf of the company, we have CEO, Robert Blum. Before I turn it over to Robert, I just wanted to highlight that there is a Q&A for those listening on the webcast. And if you get your question in there, I'm happy to kind of squeeze it in there on your behalf.

So with that, Robert, over to you.

Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director

Thank you, and thank you to JPMorgan for inviting Cytokinetics to be presenting an update here at the 2023 conference. I'm very pleased to be speaking on behalf of Cytokinetics. This is a very important year. I'll be making some forward-looking statements. I'll draw reference to the SEC filings for caveats on those statements,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot